Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 724-727

  Ke, Ruian ^a   Loverdo, Claude ^a   Qi, Hangfei ^b   Olson, C Anders ^b   Wu, Nicholas C ^a   Sun, Ren ^b,c   Lloyd smith, James O ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Hepatitis C virus; Mathematical modeling; Pharmacokinetics pharmacodynamics; Resistance

Indexed keywords

ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEPACIVIRUS; HUMAN; ISOLATION AND PURIFICATION; PLASMA; THEORETICAL MODEL; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPACIVIRUS; HUMANS; IMIDAZOLES; MODELS, THEORETICAL; PLASMA; VIRAL LOAD;

EID: 84894048352     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt423     Document Type: Article

References (15)

1. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
2. Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-35.
3. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
4. Pol S, Ghalib RH, Rustgi VK et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-7.
5. Karino Y, Toyota J, Ikeda K et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-54.
6. Nettles RE, Gao M, Bifano M et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-65.
7. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 2007; 7: 498-504.
8. Mouton JW, Theuretzbacher U, CraigWA et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.
9. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo andthe antiviral efficacyof interferon-atherapy. Science 1998;282:103-7.
10. Guedj J, Dahari H, Rong L et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 2013; 110: 3991-6.
11. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci 2000; 267: 835-43.
12. Snoeck E, Chanu P, Lavielle M et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 2010; 87: 706-13.
13. Zhou Y, Bartels DJ, Hanzelka BL et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008; 52: 110-20.
14. Chu HM, Zhou Y, Bartels DJ et al. Telaprevir (VX-950)-resistant variants exhibit reduced replication capacity compared to wild-type HCV in vivo and in vitro. J Hepatol 2007; 46.
15. Adiwijaya BS, Herrmann E, Hare B et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of proteaseinhibitor resistant variants. PLoS Comput Biol 2010; 6: e1000745.